Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~Adult Cohort: 18 to 49 years and in good health~* Highly unlikely to conceive from vaccination through 6 weeks after administration of the study vaccine.~Infant Cohort: approximately 2 months (42 to 90 days) and in good health.~Exclusion Criteria:~Adult cohort: Prior administration of any pneumococcal vaccine~* History of invasive pneumococcal disease~* Known hypersensitivity to any vaccine component~* Known or suspected impairment of immune function~* Coagulation disorder contraindicating intramuscular vaccination~* Received a blood transfusion or blood products within 6 months~* Participated in another clinical study of an investigational product within 2 months~* Breast feeding. Infant cohort: Prior administration of any pneumococcal vaccine~* Known hypersensitivity to any vaccine component~* Known or suspected impairment of immune function~* History of congenital or acquired immunodeficiency~* Has or mother has documented Human Immunodeficiency virus (HIV) infection~* Has or mother has documented hepatitis B surface antigen positive result~* Functional or anatomic asplenia~* History of failure to thrive~* Coagulation disorder contraindicating intramuscular vaccination~* History of autoimmune disease or autoimmune disorder~* Known neurologic or cognitive behavioral disorder~* Received systemic corticosteroids within 14 days~* Received other licensed non-live vaccine within 14 days~* Received other licensed live virus vaccine within 30 days~* Received a blood transfusion or blood products~* Participated in another clinical study of an investigational product~* History of invasive pneumococcal disease

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Adult: V114 Medium Dose (Type: EXPERIMENTAL): Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 on Day 1.
- Adult: V114 High Dose (Type: EXPERIMENTAL): Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 on Day 1.
- Adult: V114 Medium Dose with Alternative Carrier Protein (Type: EXPERIMENTAL): Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein on Day 1.
- Adult: V114 High Dose with Alternative Carrier Protein (Type: EXPERIMENTAL): Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein on Day 1.
- Infant: V114 Medium Dose (Type: EXPERIMENTAL): Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 at 2, 4, 6, and 12 to 15 months of age.
- Infant: V114 High Dose (Type: EXPERIMENTAL): Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 at 2, 4, 6, and 12 to 15 months of age.
- Infant: V114 Medium Dose with Alternative Carrier Protein (Type: EXPERIMENTAL): Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
- Infant: V114 High Dose with Alternative Carrier Protein (Type: EXPERIMENTAL): Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
- Infant: Prevnar 13™ (Type: ACTIVE_COMPARATOR): Infant participants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12 to 15 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete